Certara, Inc. (NASDAQ:CERT) Stake Lifted by GAMMA Investing LLC

GAMMA Investing LLC boosted its holdings in Certara, Inc. (NASDAQ:CERT - Free Report) by 751.8% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 71,726 shares of the company's stock after purchasing an additional 63,305 shares during the quarter. GAMMA Investing LLC's holdings in Certara were worth $7,245,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Versant Capital Management Inc lifted its position in Certara by 218.8% in the first quarter. Versant Capital Management Inc now owns 2,719 shares of the company's stock valued at $27,000 after acquiring an additional 1,866 shares during the last quarter. Kera Capital Partners Inc. purchased a new position in shares of Certara during the first quarter worth about $139,000. Mackenzie Financial Corp acquired a new stake in shares of Certara during the fourth quarter worth about $17,852,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Certara by 16.8% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 263,574 shares of the company's stock valued at $2,807,000 after purchasing an additional 37,870 shares during the last quarter. Finally, Voloridge Investment Management LLC lifted its holdings in shares of Certara by 269.3% in the 4th quarter. Voloridge Investment Management LLC now owns 275,633 shares of the company's stock valued at $2,935,000 after purchasing an additional 201,003 shares during the last quarter. Institutional investors and hedge funds own 73.96% of the company's stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on CERT shares. Robert W. Baird increased their price target on shares of Certara from $9.00 to $13.00 and gave the stock a "neutral" rating in a research note on Friday, April 11th. Stephens reaffirmed an "overweight" rating and set a $17.00 price objective on shares of Certara in a research note on Thursday, February 27th. TD Cowen initiated coverage on Certara in a research report on Thursday, February 27th. They set a "buy" rating and a $16.00 price objective for the company. KeyCorp boosted their target price on Certara from $15.00 to $18.00 and gave the company an "overweight" rating in a report on Wednesday, April 16th. Finally, William Blair restated a "market perform" rating on shares of Certara in a research note on Thursday, February 27th. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $15.67.

Certara Stock Down 8.2%

NASDAQ:CERT traded down $1.00 during mid-day trading on Thursday, hitting $11.18. The company had a trading volume of 4,374,709 shares, compared to its average volume of 1,379,799. The business has a fifty day simple moving average of $12.15 and a 200-day simple moving average of $11.87. The firm has a market capitalization of $1.81 billion, a price-to-earnings ratio of -55.90, a PEG ratio of 9.29 and a beta of 1.44. Certara, Inc. has a 1 year low of $8.64 and a 1 year high of $16.93. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28.

Certara (NASDAQ:CERT - Get Free Report) last released its earnings results on Monday, May 5th. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.10 by $0.04. The company had revenue of $106.00 million during the quarter, compared to analysts' expectations of $104.44 million. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The business's revenue was up 9.7% on a year-over-year basis. During the same period in the prior year, the business posted $0.10 EPS. Equities analysts forecast that Certara, Inc. will post 0.28 earnings per share for the current fiscal year.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.